tm logo
PINOVA THERAPEUTICS
Live/Pending
FIRST EXTENSION - GRANTED

granted

on 02 Mar 2024

Last Applicant/ Owned by

4701 Sangamore Road, #100N

Bethesda

MD

20816

Serial Number

97135396 filed on 19th Nov 2021

Registration Number

N/A

Correspondent Address

Spencer Wolff Esquire

Spencer Wolff Law PC

48 Morton Street

New York,NY 10014

Filing Basis

1. intent to use

2. intent to use current

Disclaimer

"THERAPEUTICS"

PINOVA THERAPEUTICS

scientific research and development into treatments of opioid dependence, benzodiazepine dependence, anaphalytic shock, seizures, hypoglycemia, neurodegenerative disorders, allergies, blood pressure, acute chest pain, mastocytosis disease, pain management, anxiety, post-traumatic stress disorder, sleep disorders, hypercalcaemia, osteoporosis, migraines, hormone replacement therapy, smoking cessatiRead More

Classification Information


Class [044]
Medical, Beauty & Agricultural Services


medical and healthcare information services namely providing medical and healthcare information in the fields of opioid dependence, benzodiazepine dependence, anaphalytic shock, seizures, hypoglycemia, neurodegenerative disorders, allergies, blood pressure, acute chest pain, mastocytosis disease, pain management, anxiety, post-traumatic stress disorder, sleep disorders, hypercalcaemia, osteoporosis, migraines, hormone replacement therapy, smoking cessation, nausea, motion sickness, heartburn, indigestion, acid reflux, hemophiliac bleeding, urinary incontinence, mood disorders, vitamin deficiencies, low phosphate levels, diarrhea, asthma, chronic obstructive pulmonary disease, endometriosis, and early puberty

Class [042]
Computer & Software Services & Scientific Services


scientific research and development into treatments of opioid dependence, benzodiazepine dependence, anaphalytic shock, seizures, hypoglycemia, neurodegenerative disorders, allergies, blood pressure, acute chest pain, mastocytosis disease, pain management, anxiety, post-traumatic stress disorder, sleep disorders, hypercalcaemia, osteoporosis, migraines, hormone replacement therapy, smoking cessation, nausea, motion sickness, heartburn, indigestion, acid reflux, hemophiliac bleeding, urinary incontinence, mood disorders, vitamin deficiencies, low phosphate levels, diarrhea, asthma, chronic obstructive pulmonary disease, endometriosis, and early puberty; pharmaceutical research and development into treatments of opioid dependence, benzodiazepine dependence, anaphalytic shock, seizures, hypoglycemia, neurodegenerative disorders, allergies, blood pressure, acute chest pain, mastocytosis disease, pain management, anxiety, post-traumatic stress disorder, sleep disorders, hypercalcaemia, osteoporosis, migraines, hormone replacement therapy, smoking cessation, nausea, motion sickness, heartburn, indigestion, acid reflux, hemophiliac bleeding, urinary incontinence, mood disorders, vitamin deficiencies, low phosphate levels, diarrhea, asthma, chronic obstructive pulmonary disease, endometriosis, and early puberty; pharmaceutical research and development into treatments of opioid dependence, benzodiazepine dependence, anaphalytic shock, seizures, hypoglycemia, neurodegenerative disorders, allergies, blood pressure, acute chest pain, mastocytosis disease, pain management, anxiety, post-traumatic stress disorder, sleep disorders, hypercalcaemia, osteoporosis, migraines, hormone replacement therapy, smoking cessation, nausea, motion sickness, heartburn, indigestion, acid reflux, hemophiliac bleeding, urinary incontinence, mood disorders, vitamin deficiencies, low phosphate levels, diarrhea, asthma, chronic obstructive pulmonary disease, endometriosis, and early puberty; pharmaceutical research and development into treatments of opioid dependence, benzodiazepine dependence, anaphalytic shock, seizures, hypoglycemia, neurodegenerative disorders, allergies, blood pressure, acute chest pain, mastocytosis disease, pain management, anxiety, post-traumatic stress disorder, sleep disorders, hypercalcaemia, osteoporosis, migraines, hormone replacement therapy, smoking cessation, nausea, motion sickness, heartburn, indigestion, acid reflux, hemophiliac bleeding, urinary incontinence, mood disorders, vitamin deficiencies, low phosphate levels, diarrhea, asthma, chronic obstructive pulmonary disease, endometriosis, and early puberty

Class [005]
Pharmaceutical Products


pharmaceutical preparations for the treatment of opioid dependence, benzodiazepine dependence, anaphalytic shock, seizures, hypoglycemia, neurodegenerative disorders, allergies, blood pressure, acute chest pain, mastocytosis disease, pain management, anxiety, post-traumatic stress disorder, sleep disorders, hypercalcaemia, osteoporosis, migraines, hormone replacement therapy side effects, smoking cessation, nausea, motion sickness, heartburn, indigestion, acid reflux, hemophiliac bleeding, urinary incontinence, mood disorders, vitamin deficiencies, low phosphate levels, diarrhea, asthma, chronic obstructive pulmonary disease, endometriosis, and early puberty

Mark Details


Serial Number

No 97135396

Mark Type

No Service Mark

Attorney Docket Number

No

44D Filed

No

44D Current

No

44E filed

No

44E Current

No

66A Filed

No

66A Current

No

Current Basis

No

No Basis

No

Legal History


Show more

Status DateAction Taken
05th Mar 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
02th Mar 2024SOU TEAS EXTENSION RECEIVED
02th Mar 2024SOU EXTENSION 1 FILED
02th Mar 2024SOU EXTENSION 1 GRANTED
12th Sep 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
18th Jul 2023PUBLISHED FOR OPPOSITION
18th Jul 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
28th Jun 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
08th Jun 2023APPROVED FOR PUB - PRINCIPAL REGISTER
11th May 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED